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DISSECTING THE MOLECULAR MECHANISM OF EARLY TUMOR
DISSEMINATION IN NON-SMALL CELL LUNG CANCER

By Xingtong Liu, B.S.

Advisor: Xiangwei Wu, Ph.D.

Abstract
Lung cancer is the most common cause of cancer related death in the United States and
worldwide. It has been shown that disseminated tumor cells were detected in 40% of the
lymph nodes of patients during the surgery. Furthermore, 30%-55% of patients with early
stages of non-small cell lung cancer (NSCLC) developed and died of recurrence after
curative resection. These evidence confirmed that tumor cell dissemination occurred early in
those patients before surgery. However, underling mechanisms and risk factors for the
NSCLC relapse remain largely unknown. Addressing these questions will be critical for the
development of strategies to determine the risk of recurrence and formulate approaches to
reduce these risks. My thesis focuses on dissecting the molecular basis of early tumor cell
dissemination (ETCD) using mouse models of NSCLC. First, we established and
characterized a new mouse model of NSCLC using lung-specific activation of an epidermal
growth factor receptor (EGFR) mutant form in combination with loss of p53. Using this
model and an oncogenic Kras–driven lung cancer model, we identified that the combination
of inflammation and stress is a major contributor in inducing ETCD. A small number of the
early disseminated tumor cells (<100) at an adenoma stage were able to form lung tumors
and tumors in other organs when introduced into wild type syngeneic mice. Furthermore, we
v

identified a pathway that is initiated by inflammation and stress signals which activates
monocytes as the major cell type. The activated monocytes promote both the invasiveness of
adenoma cells and increases the leakiness of the blood vessels for ETCD via the induction of
TGF-β and MMP-9. Consistent with our findings, a retrospective analysis of data,
comprising of over 2,000 NSCLC patients, revealed that patients that used both aspirin and
β-adrenergic antagonists had a significantly reduced risk in cancer recurrence compared to
non-users. This finding was confirmed in the mouse model as the application of a non-sterol
anti-inflammatory drug in combination with a β-blocker completely blocked ETCD. Our
data strongly support the utility of aspirin and β-blocker uptake as an indicator for assessing
recurrence risk in NSCLC patients and targeting these pathways may represent a valid
approach in preventing ETCD and recurrence in people with high risk of developing lung
cancer.

vi

Table of Contents

Approval Page ............................................................................................................................. i
Title Page ................................................................................................................... ii

Dedication ................................................................................................................. iii

Acknowledgements .................................................................................................... iv

Abstract ..................................................................................................................... v

Chapter 1 Introduction............................................................................................... 1
1.1 Lung cancer ............................................................................................................... 1
1.2 EGFR mutations in lung cancer .................................................................................. 4
1.3 Early tumor dissemination .......................................................................................... 6
1.4 CTC detection methods ............................................................................................ 11
1.5 Inflammation ............................................................................................................ 14
1.6 Stress ...................................................................................................................... 16
1.7 Monocytes involved in tumor dissemination. .............................................................. 18
1.8 TGF-β and MMPs..................................................................................................... 19
1.9 Significance of this study .......................................................................................... 22

vii

Chapter 2 Materials and Methods. ............................................................................23
2.1 Loss of p53 is required for non-amplified EGFRvIII to induce lung cancer in mice ......... 23
2.1.1 Mouse breeding, adeno-cre virus installation and tumor analysis .......................... 23
2.1.2 CTC detection and isolation .................................................................................. 24
2.1.3 Tumorigenesis assays .......................................................................................... 25
2.1.4 TGF-β inhibitor treatment ...................................................................................... 25
2.1.5 Statistical analysis................................................................................................. 26
2.2 Characterize early tumor dissemination in NSCLC..................................................... 26
2.2.1 Cell culture ............................................................................................................ 26
2.2.2 Mice ...................................................................................................................... 27
2.2.3 In vivo treatment ................................................................................................... 27
2.2.5 Invasion and permeability assay ........................................................................... 29
2.2.6 Western blot analysis. ........................................................................................... 30
2.2.7 Study patient selection .......................................................................................... 30
2.2.8 Statistical analysis. ................................................................................................ 31

Chapter 3 Loss of p53 is required for non-amplified EGFRvIII to induce lung cancer in
mice ........................................................................................................................32
viii

3.1 Introduction .............................................................................................................. 32
3.2 Non-amplified EGFRvIII mutation requires loss of p53 to induce lung tumorigenesis..... 33
3.3 Late tumor cell dissemination in EP mice .................................................................. 36
3.4 CTCs have tumor-forming capacity in syngeneic wildtype mice. ................................. 38
3.5 Blocking TGF- β signaling inhibited tumor cell dissemination in EP mice .................... 40
3.6 Conclusion and Discussion ....................................................................................... 42

Chapter 4. Characterization the molecular mechanism of early tumor dissemination in
non-small cell lung cancer ........................................................................................45
4.1 Introduction .............................................................................................................. 45
4.2 Early disseminated tumor cells are tumorigenic. ........................................................ 49
4.3 Combination of inflammation and stress is sufficient to induce ETCD. ........................ 52
4.4 Role of monocytes in ETCD ...................................................................................... 55
4.5 Activated monocytes induce the invasiveness of adenoma cells and leakiness of blood
vessels. ......................................................................................................................... 59
4.6 Induced expression of TGF- β1 and MMP-9 in monocytes as the mechanism of ETCD
..................................................................................................................................... 64
4.7 Simultaneous targeting of inflammation and stress inhibits ETCD............................... 72

ix

4.8 Retrospective analysis of clinical data ....................................................................... 74
4.9 Conclusion and Discussion ....................................................................................... 77

Chapter 5 Summaries and Discussion ......................................................................79
5.1 Early cancer detection .............................................................................................. 79
5.2 Management of NSCLC recurrence .......................................................................... 85

Bibliography .............................................................................................................88

VITA ...................................................................................................................... 105

x

List of Figures
Figure 1. Estimated new cases and death caused by cancers.................................... 3

Figure 2. Tumor progression model. .......................................................................... 9

Figure 3. Schematic presentation of CTC isolation based on invasive phenotype. .....13

Figure 4. TGF- β signaling pathway. .........................................................................21

Figure 5. Analysis of tumor progression in LSL-EGFRvIII/+, LSL-Trp53fl/fl (EP) mice. ...35

Figure 6. Isolation and Identification of invasive CTCs in EP mice. ............................37

Figure 7. CTCs have tumor-forming capacity in syngeneic wildtype mice. .................39

Figure 8. Effect of SB431542 on tumor dissemination of EP mice. ............................41

Figure 9. Detection of CTCs in EP mice....................................................................47

Figure 10. Detection of CTCs in LSL-KrasG12D mice. .................................................48

Figure 11. Gross morphology and H&E staining of lung and liver tumors formed by CTCs
of FWEP mice. ........................................................................................................ 51

Figure 12. Involvement of acute stress and inflammation in ETCD of EP mice. .........53

xi

Figure 13. Involvement of acute stress and inflammation in ETCD of LSL-KrasG12D mice
............................................................................................................................... 54

Figure 14. Role of monocytes in ETCD of EP mice. ..................................................57

Figure 15. Role of monocytes in ETCD of LSL-KrasG12D mice. ..................................58

Figure 16. Lung blood vascular leakage induced by fighting-wound ..........................61

Figure 17. Effect of LPS- and ISO-activated monocytes on endothelial permeability and
tumor cell invasion .................................................................................................. 62

Figure 18. Effect of LPS- and ISO-activated THP-1 cells on endothelial permeability and
tumor cell invasion .................................................................................................. 63

Figure 19. MMP antibody array identified MMP-9 as a downstream mediator. .......... 66

Figure 20. Increased expression of TGF-β1 and MMP-9 in the monocytes of FWEP mice
and in THP-1 cells treated by LPS, ISO, and in combination. ................................... 67

Figure 21. Induction of MMP-9 by TGF- β1 in mouse monocytes and THP-1 cells. ....68

Figure 22. TGF-β inhibitor inhibited ETCD. ...............................................................69

xii

Figure 23. MMP-9 inhibitor suppressed ETCD. .........................................................70

Figure 24. Effect of MMP-9 overexpression in THP-1 cells on endothelial permeability
and tumor cell invasion ........................................................................................... 71

Figure 25. Effect of sulindac and propranolol treatment on ETCD. ............................73

Figure 26. Detection of CTCs in pre-malignant ApcMin/+ mice.....................................82

Figure 27. Detection of CTCs in FAP and HNPCC patients with InCTC assay. ..........83

xiii

Lists of Tables
Table 1. Retrospective studies of survival and recurrence in early stage NSCLC patients
after surgery. ............................................................................................................................. 10
Table 2. Tumor formation and dissemination site of control PBMC or CTC transfused
syngeneic mice .......................................................................................................................... 50
Table 3. Effect of aspirin and β-blocker use on lung cancer recurrence ............................. 76

xiv

Chapter 1 Introduction
1.1 Lung cancer

According to cancer statistics in 2017, lung cancer is the leading cause of cancer

deaths with a high incidence rate in the United States and worldwide [1](Figure 1). Despite

over 30 years of progress in early diagnosis and standard treatment, the benefit is limited as

the overall 5-year survival rate is still as low as 18%. The survival rate improves dramatically

when patients are diagnosed at early stage such as IA and IB [2]. For now, the only

recommended lung cancer screening method is low-dose computed tomography (LDCT) [3],

which reduces risks of dying from lung cancer. However, LDCT is limited in that it cannot

detect all types of lung cancers or detect all lung cancers early. That, and false-positive results

generated compromise the benefits [4]. Overall, early detection of lung cancer is infrequent

and serendipitous. Therefore, developing an accurate early detection method for lung cancer

is sorely needed.

Broadly, lung cancer is divided into two main histopathological subtypes: non-

small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC) [5]. SCLC, a highly
1

aggressive and lethal lung cancer, is strongly related to smoking and occurs in current or

former smokers. SCLC is characterized by fast tumor growth, early dissemination, genomic

instability and initial sensitivity to chemotherapy and radiotherapy [6]. Uniformly, loss of

function of tumor suppressor gene TP53 and Retinoblastoma susceptibility gene (RB1) were

recognized as the most striking alterations found in SCLC patients [7, 8]. Activation of

oncogenes, like C-MET, MYC, BCL2, Phosphatidylinositol 3 kinase (PI3K) pathway and

NOTCH pathway were identified to be associated with SCLC [9].

NSCLC accounts for 85% of lung cancer cases. It can be further categorized into

three subtypes based on histopathological findings, adenocarcinoma (ADC, around 30-35%),

squamous cell carcinoma (SCC, around 30-35%) and large cell carcinoma (around 10%) [5].

Generally, SCC is believed to arise from proximal airways, whereas ADC arises from more

distal locations [10]. NSCLC not only comprises of diverse histopathological subtypes, but

also harbors diverse driver mutations, including EGFR, KRAS, MEK1/2, HER2, BRAF, PI3K

and EML4-ALK [11]. Among those driver genes, mutations of EGFR are noted in 15-50% of

NSCLC [12, 13].

2

Figure 1. Estimated new cases and death caused by cancers.
Lung and bronchus cancers rank second in new increased cases and accounts for the most death
caused by cancer in 2017 in both male and female.
Adapted and with permission from American Cancer Society, Cancer Facts & Figures 2017.
Atlanta: American Cancer Society; 2017.
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1.2 EGFR mutations in lung cancer.

Epidermal growth factor receptor (EGFR) belongs to the ErbB family of receptor

tyrosine kinase (RTK). It mediates cell signaling via several extracellular ligands, including

epidermal growth factor (EGF), transforming growth factor-α (TGF-α), betacellulin (BTC),

amphiregulin (AREG), heparin-binding, epigen (EPGN), and epiregulin (EREG)[14-16]. Like

all RTKs, EGFR contains a large extracellular domain, a single spinning transmembrane (TM)

domain, an intracellular juxtamembrane (JM) region, a tyrosine kinase domain and a C terminal

regulatory region [17]. The EGFR protein is expressed in some neurogenic, epithelial and

mesenchymal tissues. Deregulation of EGFR is highly correlated with human malignancies.

Overexpression of EGFR has been found in cancers of the brain, ovary, cervix, bladder, head

and neck, stomach, endometrium, colon and lung, and frequently seems to infer poor prognosis

[18-21]. EGFR mutations are also widely present among various cancer types, especially

NSCLC. EGFR mutations are present in nearly 10% of cases in the United States, but 30-50%

cases of East Asian individuals diagnosed with NSCLC [13, 22-24]. Two of the most common

EGFR mutations are in-frame deletions in exon 19 and L858R substitution in exon 21. The
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presence of either of the two kinase domain mutations would lead to increased kinase activity of

the receptor and further upregulate certain cellular signaling pathways, thus result in cell

proliferation, migration and survival [25]. Deletions of the extracellular domain of EGFR also

frequently occur in lung cancer and glioblastoma multiforme (GBM) [26-28]. It can be divided

into EGFR vI, EGFR vII, and EGFR vIII based on the site and length of the mutation [29].

EGFRvIII mutation, with a deletion of exon 2 to exon 7 from the extracellular domain, was

identified at a more than 39% frequency in Glioblastoma Multiforme (GBM) patients and was

able to produce constitutively active EGFR activity without binding to specific ligands [27, 30].

The proportion of EGFRvIII mutation in lung cancer varies greatly depending on the cancer type

and patient population. It was identified in 16-39% of NSCLC patients by

immunohistochemical analysis, whereas a much lower proportion of EGFRvIII expression was

found by another two studies utilizing RT-PCR to determine the EGFRvIII mutation [31-33]. One

interesting finding is that the EGFRvIII mutation in lung cancer correlates with increased EGFR

copy number [33]. Overexpression of EGFRvIII mutant in mice under the control of a

tetracycline inducible promoter resulted in the development of lung adenocarcinoma after 16

5

weeks of induction [32]. However, the role of non-amplified EGFRvIII mutation in lung

tumorigenesis is not yet fully understood and thus needs to be elucidated. Studies in GBM have

shown that endogenous EGFRvIII needs to cooperate with tumor suppressor gene loss or

mutation in order to initiate tumorigenesis [34]. Therefore, in this thesis, my first aim was to

investigate the role of the non-amplified EGFRvIII mutation and its interaction with the p53

mutation in lung tumorigenesis.

1.3 Early tumor dissemination

Tumor dissemination, where tumor cells enter into the lymphatic system or blood

circulation through invasion and migration, is a hallmark of tumor progression that can

potentially lead to the establishment of clinically detectable metastases [35]. It is generally

thought that tumor cell dissemination is a late event after extensive expansion of primary

tumors. However, contrary to the prevailing hypotheses, emerging evidence indicates that

dissemination of tumor cells could occur from the earliest pre-neoplastic lesions through a

multiple-step process known as the invasion-metastasis cascade, sometimes even before the

establishment of observable primary tumors (Figure 2) [35]. It has been shown that

6

untransformed mouse mammary cells expressing inducible oncogenes can survive in the

bloodstream and in the lung without oncogene activation, and further develop into metastatic

pulmonary malignancies upon immediate or delayed activation of oncogenes [36]. Analysis of

breast cancer progression showed that tumor cells were disseminated systematically from

early epithelial alterations in HER-2 and PyMT transgenic mice and from ductal carcinoma in

situ (DCIS) in women [37]. Using a spontaneous mouse model of melanoma, tumor cells

were identified to disseminate throughout the body early in the formation of the primary

tumor, even before it became clinically detectable [38]. In genetically modified mouse models

of pancreatic cancer, pre-neoplastic tumor cells were found in the blood circulation and

seeded distant organs before aggressive malignancy could be detected [39]. Consistent with

animal model studies, circulating tumor cells (CTCs) were identified in patients with benign,

premalignant, and malignant pancreatic lesions, but not in healthy volunteers [40, 41]. Early

tumor dissemination was observed in almost all the cancer types, including NSCLC (Figure

3). Disseminated tumor cells were detected in 40% of the lymph nodes of patients during the

surgery [42]. Furthermore, after complete resection surgery, 30%-55% of NSCLC patients

7

develop recurrence and die of the disease [42, 43]. However, in animal models of NSCLC, the

conclusion seems to be controversial in the way that we and others detected tumor

dissemination only in the advanced adenocarcinoma stages [44, 45]. Hence, the second aim of

my thesis was to identify additional essential events required for early tumor cell

dissemination (ETCD) in NSCLC mouse models and to develop innovative NSCLC

preventive approaches based on molecular events and mechanisms.

8

Figure 2. Tumor progression model.
Tumor dissemination occurs early during tumor progression. After extravasation, dormant
CTC/DTCs are able to invade into the blood vessel and form metastasis.
Adapted and with permission from Xiangwei Wu, [Powerpoint slides] “New Approaches in
Cancer Early Detection and Chemoprevention,” Cancer Prevention and Control Grand Rounds,
M.D. Anderson Cancer Center.
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Author

Stage

Year

Patients

5 year Survival

Recurrencea

van den Berg[46]

Stage I

2015

143

58.2%

22% (2 year)

Lee[47]

Stage I and II

2015

249

N.A.

33.5%(5 year)

Kastelijn[48]

Stage I and II

2015

175

70% (3 year)

35% (5 year)

Choi[49]

Stage IA and IB

2014

242

75.7% and 57.3%

31.8% (5 year)

Zhu[50]

Stage I and II

2014

994

59%

25.7% (5 year)

CrabTree[51]

Stage I

2014

458

64%

22.3% (2 year)

Boyd[52]

Stage I and II

2010

975

N.A.

36% (5 year)

Hung[53]

Stage I

2009

933

51.70%

31% (5 year)

Table 1. Retrospective studies of survival and recurrence in early stage NSCLC patients after
surgery.
Summary of retrospective studies from 2008-2017 of survival and recurrence rate in early stage
NSCLC patients. N.A. indicates not applicable. a Recurrence includes local, distant or local and
distant recurrence of patients followed 2 or 5 years after surgery.
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1.4 CTC detection methods

As the intermediate population of primary tumor and distant metastasis, CTCs have

exhibited great potential as a liquid biopsy-based biomarker for detecting cancer at an early

stage, monitoring cancer treatment efficacy and predicting clinical impact [54, 55]. CTCs are

rare (1-10 cells per 10 mL in most cancer patients) in the peripheral blood. All CTC isolation

and detection methods face the common challenge of purifying the rare CTCs while limiting

the impact of contaminating leukocytes [56]. In the recent decades, great advances have been

made in CTC isolation and detection technologies [56, 57]. The most popular CTC isolation

technology involves the antibody-mediated capture and selection, like CellSearch system and

CTC-Chip platforms. This technology makes use of magnetic antibodies against the common

epithelial cell marker EpCAM on cancer cells. CellSearch is already approved by the FDA to

determine therapeutic efficacy for patients with colorectal, prostate or metastatic breast cancer

[58-60]. Other technologies may take advantage of the fact that many epithelial tumor cells

are larger than leukocytes, like ScreenCell [61, 62]. ScreenCell utilizes a filtration based

mini-device that isolates CTCs from leukocytes in a blood sample depending on different cell

11

size. Some technologies are making use of the proteins secreted by functional CTC/DTCs in

combination with negative enrichment, like the EPISPOT assay [63]. However, CTCs are a

heterogeneous population of cells with different cell size, variable expression of EpCAM and

distinct secreted proteins [64]. Thus, these characteristics limit the use of all these

technologies. Furthermore, some CTCs may originate from mechanical disturbing process or

surgical resection rather than through active invasion-migration cascade, and some CTCs may

lose their viability or functionality and thus become irrelevant to cancer metastasis [65].

Therefore, CTC analysis with these technologies may yield low sensitivity or specificity in

cancer detection, predicting cancer outcome and treatment response. To circumvent the

limitations of current methods, we developed a novel method for isolation, detection, and

analysis of CTC that is based on the fact that tumor cells enter circulation by gaining the

ability to migrate and invade. The hypothesis is that functional CTCs retain this invasive

property and that they can be identified in vitro using a matrigel invasion assay. We

designated this innovative method “Invasion-based CTC discovery assay,” abbreviated as

“InCTC” (Figure 3).

12

Figure 3. Schematic presentation of CTC isolation based on invasive phenotype.
Blood was isolated from subjects. CTC containing peripheral mononuclear cells were separated
by Ficoll gradient centrifugation and subjected to transwell for invasion assay. CTCs would then
be counted and stained with specific markers.
Adapted from Liu X and Wu X. Methods Mol Biol. 2017. Figure reprinted by permission from
Methods in Molecular Biology journal of HUMANA PRESS Inc.
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1.5 Inflammation

Inflammation is defined as the body’s immediate biological response to the damages

to the cells and tissues from different sources, such as pathogens, obesity and environmental

stimuli [66]. Inflammation is a complex process involving the dynamic alteration of

microenvironment orchestrated by immune cells, stroma cells, chemokines and cytokines

[67]. Inflammation can be categorized as acute or chronic inflammation depending on the

duration and distinct characteristics. Acute inflammation involves three major factors: (1)

Increase in blood flow by alterations in vascular caliber. (2) Increase of vascular permeability

to allow leukocytes to leave circulation. (3) Leukocytes would be accumulated and activated

in the injury site to eliminate the offending sources [68]. If the offending sources were not

eliminated in a short term, the long lasting inflammatory process would gain other

characteristics and thus become chronic inflammation. Chronic inflammation affects all the

stages of tumor development, including initiation, promotion, invasion and metastasis [69].

Induction and continuation of inflammation predisposes people to a higher risk of various

cancer types [69-71].

14

Acute inflammation eliminates the offending pathogens and repairs the injured tissues.

Acute inflammation was used by Coley in 1890s to treat cancer with some success [72]. Even

now, the microbial preparations formulated by Coley are utilized for bladder squamous

cancer therapy [72]. The application of induced acute inflammation as a cancer therapy has

shown to be beneficial.

The inflammatory process involves monocytes, macrophages, neutrophils, basophils,

dendritic cells, mast cells, T-cells, and B-cells. In addition, cytokines and chemokines

produced by leukocytes exhibit dynamic roles in this process. The complexity of the

participants in acute inflammation and their functions would result in an unpredictable

outcome in tumor cell dissemination, thus offsetting the benefits. [73, 74]. Cytokines, such as

TNF-α, IL-10, TGF-β, and IL-6 have been shown to participate in the initiation, progression

and metastasis of cancer [69, 75]. Leukocytes interact with CTCs directly and indirectly to

promote tumor dissemination. Platelets are generated and released into the blood stream by

the precursor cells megakaryocytes. Platelets are reported to promote CTC dissemination by

contributing to the survival of CTCs in the blood stream, extravasation and establishment of

15

metastasis via activation and formation of a platelet-cancer cell aggregate [76, 77]. Clinical

data and select animal models indicate that elevated neutrophils are correlated with a higher

risk of metastasis [78, 79]. In breast cancer mouse models, neutrophils could selectively

propagate tumor cells with higher tumorigenic potential by localizing to the lung and

producing leukotrienes or through dampening antitumor T-cell immunity [80, 81].

Inflammatory conditions were reported to stimulate neutrophil extracellular traps (NET) that

were capable of trapping CTCs and thus promoting lung metastasis formation [82].

Monocytes are also one of the immune cell types that contribute to tumor dissemination and

described in Chapter 1.8

1.6 Stress

Despite various aspects of stress that have been thoroughly investigated, researchers still

have not achieved a satisfactory definition on stress. The Selye (1956) defined stress as any

stressors that seriously threaten homeostasis between internal milieu and changing

environment [83]. Stress affects immunological functions through various mechanisms. Stress

response physiologically involves activation of body systems, including the
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sympathoadrenomedullary system (SNS) and the hypothalamic–pituitary–adrenal (HPA) axis

[84, 85]. These body systems secrete neurotransmitters, neuropeptides, neurohormones and

adrenal hormones, especially epinephrine (E), norepinephrine (NE) and cortisol. NE and E

regulate leukocyte function and induce leukocytes with adrenergic receptors to be re-

distributed through adrenergic pathways. [86]. Meanwhile, chronic stress has been reported to

mediate lymphocyte apoptosis via the upregulation of Fas expression [87]. Furthermore,

stress has been demonstrated to compromise natural killing cell activity in both animal model

and clinical studies[88, 89]. Finally, stress has also been shown to promote ovarian cancer

growth and liver metastasis formation by directly upregulating vascular endothelial growth

factor (VEGF) and matrix metallopeptidases (MMPs) in cancer cells [90]. In summary,

through secreted hormones like E and NE, stress signals could directly influence tumor

progression and indirectly affect tumor cells through the modification of immunological

functions of the surrounding leukocytes.

17

1.7 Monocytes involved in tumor dissemination

Monocytes are a subset of bone marrow-derived myeloid cells that circulate in the blood

system. They belong to leukocyte populations and participate in a paradoxical conspicuous

role in tissue homeostasis and immunity [91]. Sub-populations of monocytes are classified by

the location, phenotype, morphology and characteristic gene signatures. Generally, monocyte

subsets are identified by the expression of Ly6c, CX3CR1 and GR1 [91]. Classical

inflammatory monocytes, defined as CCR2highLy6c+GR1+, are reported to be recruited to the

tumor site by tumor cells or circulating fibrocytes that secrete CCL-2 and contribute to tumor

dissemination through monocyte-derived VEGF [92, 93]. Patrolling monocytes were

identified as CX3CR1highLy6C– and have been shown to suppress lung metastasis by

eliminating tumor cells directly and activating natural killing cells in a CX3CR1-dependent

manner [94]. It is also reported that CXCR3+ monocytes are required for sufficient tumor

engraftment in lungs [95]. Therefore, based on different stimulation to monocytes, the sub-

population of monocytes could play an entirely different role in regulating tumor

dissemination through various molecular mechanisms.

18

1.8 TGF-β and MMPs

The TGF-β superfamily comprises of more than 30 different members, including Bone

Morphogenetic Proteins (BMPs), Nodals, Growth and Differentiation Factors (GDFs),

Activins and TGF-βs [96]. They share common characteristics such as structure, synthesis,

signal transduction mechanisms and regulation [97]. The TGF-β signaling pathways

participate in regulating cell growth, proliferation, differentiation, apoptosis, angiogenesis,

migration and invasion, immune regulation, and microenvironment modification [98, 99].

Increased TGF-β expression has been observed in numerous cancer types [100-102]. In early

stage tumors, TGF-β is recognized as a tumor suppressor since it can induce cell cycle arrest

and apoptosis of premalignant epithelial cells [101]. But in the advanced stage tumors,

deregulation of TGF-β could promote tumor progression and metastasis by promoting tumor

cell invasion, EMT, and cell stemness [103, 104]. The complex, dual role of TGF- β in tumor

progression has also compromised the clinical use of TGF- β inhibition in cancer treatment

[98]. It has been adequately characterized that TGF-β binds to its receptor on the membrane

19

and induces a signaling cascade via the SMAD-mediated canonical pathway or the SMAD-

independent non-canonical pathway [98, 105] (Figure 4).

MMPs belong to a family of zinc-dependent proteases and function to degrade

structural components of the extracellular matrix (ECM). Most mammalian MMPs share

common domain structures, including an autoinhibitory pro-domain, a catalytic domain and

hemopexin-like C terminal domain [106]. MMPs participate in tissue remodeling and tissue

repair in response to injury or disease [107]. They also contribute to a pro-inflammation or

anti-inflammation role depending on the context [108]. In addition, MMPs produced by tumor

cells are believed to promote extravasation by the disruption of basement membrane and

facilitating the subsequent invasion process [109]. But recently, this notion has been revised

based on the observation that inflammatory cells within in the tumor microenvironment

would produce MMPs and thus stimulate tumor dissemination [110].
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Figure 4. TGF- β signaling pathway.
TGF-β can bind to its receptor on the membrane and induce a signaling cascade via the SMADmediated canonical pathway or the SMAD-independent non-canonical pathway.
Adapted from Neuzillet C et al., Pharmacol Ther, 2015. Figure reprinted by permission from
Pharmacology & Therapeutics journal of Elsevier.
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1.9 Significance of this study

Emerging evidence indicates that early tumor dissemination occurs in NSCLC, but the

underlying molecular mechanisms and potential risk factors for recurrence are still not well

elucidated. My dissertation focuses on dissecting the molecular mechanisms of early tumor

dissemination in the mouse model of NSCLC. To achieve this goal, I have established and

characterized the CAG-LSL-EGFRvIII/+; Trp53fl/fl (EP) mouse model (Aim 1). This model is

useful in investigating EGFRvIII-driven NSCLC progression and developing new therapies for

lung cancer. We have established a novel CTC detection method named InCTC assay. By

applying the InCTC assay to EGFRvIII- and KRASG12D-driven mouse models of NSCLC, I

have discovered that the combination of acute inflammation and stress is capable of

activating monocytes to promote early tumor cell dissemination (ETCD) in NSCLC. I have

investigated the molecular mechanism of how activated monocytes promote ETCD and

present a valid approach to prevent ETCD in NSCLC and recurrence in people with high risk

of developing lung cancer (Aim 2).
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Chapter 2 Materials and Methods.
2.1 Loss of p53 is required for non-amplified EGFRvIII to induce lung cancer in mice

2.1.1 Mouse breeding, adeno-cre virus installation and tumor analysis

All animal studies were reviewed and approved by The University of Texas MD Anderson

Cancer Center Institutional Animal Clinical Care and Use Committee. CAG-LSL-EGFRvIII/+ mice

and p53 floxed mice (Trp53fl/fl) were obtained from the NCI Mouse Repository, and breeding

colonies were established. EP mice were generated by selective breeding of CAG-LSL-EGFRvIII/+

mice with Trp53fl/fl mice. Lung tumors were induced in each of the three models as described

previously [111]. Briefly, 6-week-old mice were transiently infected with 2.5 × 108 plaque-

forming units of adeno-cre virus (Viral Vector Production Core, Baylor College of Medicine) via

two intranasal instillations of 62.5 uL of AdCre:CaPi coprecipitates. [111]. All the animals were

sacrificed at the time indicated by asphyxiation with CO2 and subjected to full necropsy. Tumor

invasiveness was determined by examination of tissues at various sites as described
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previously[112].

2.1.2 CTC detection and isolation

InCTC assay to detect and isolate CTCs was performed as described previously [113].

Briefly, blood was collected from the animal via terminal cardiac puncture and placed into tubes

containing heparin solution. CTCs were enriched by performing density gradient centrifugation.

After enrichment, cells were washed with serum-free Roswell Park Memorial Institute (RPMI)

1640 medium and placed in a matrigel-coated transwell invasion chamber for invasion assay. For

CTC detection, after invasion assays, cells were stained with pan-cytokeratin and CD45 by

immunofluorescence staining. For CTC isolation, invasive CTCs were trypsinized and cultured in

Roswell Park Memorial Institute 1640 medium with 10% fetal bovine serum. CTCs were

validated by performing PCR to detect recombinant p53 alleles. Briefly, genomic DNA was

extracted from the invasive CTCs using the QIAamp DNA Mini Kit. Thermocycling conditions

consisted of 30 cycles of 30 seconds at 94°C, then 1 minute at 55°C, then 1 minute at 72°C,

yielding a 612-bp product for recombinant p53 allele and a 283-bp product for normal p53 allele

as a control. The primers used were p53-1F (CAC AAA AAC AGG TTA AAC CCA), p53-1R
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(GGA GGC AGA GAC AGT TGG AG), and p53-10R (GAA GAC AGA AAA GGG GAG GG).

2.1.3 Tumorigenesis assays

For subcutaneous injection experiments, 5 × 106 isolated CTCs were injected into

the right dorsal flank of C57BL/6J mice (The Jackson Laboratory, Bar Harber, Maine). Tumor

progression was monitored by measuring tumor volume and body weight. Tumor size was

measured as described previously [114].

2.1.4 TGF-β inhibitor treatment

EP mice at 13 weeks after adeno-cre infection were divided randomly into two groups:

the control group, receiving phosphate-buffered saline treatment, and the treatment group. The

treatment group received daily intraperitoneal injections of the TGF-β inhibitor SB431542 at a

dose of 10 mg/kg/mouse for 1 week. Mice were sacrificed by asphyxiation with CO2 24 hours

after the last injection. Blood was collected by cardiac puncture; and lungs, livers, kidneys, and

spleens were fixed immediately in 4% paraformaldehyde, embedded in paraffin, sectioned into 5-

μm slides, and stained with hematoxylin and eosin (H&E). CTC number was determined by
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performing InCTC assays as described above[113].

2.1.5 Statistical analysis

We compared groups via Student t-test. P values of <0.05 were considered
statistically significant. Survival curve of EP mice, CAG-LSL-EGFRvIII/+ mice and
Trp53fl/fl mice were generated using Kaplan-Meier estimate, and difference between each

group was analyzed by log-rank test.

2.2 Characterize early tumor dissemination in NSCLC

2.2.1 Cell culture

HBE4-E6/E7 cell line was obtained from ATCC. THP-1 cells were kindly provided by Dr.

Michael Andreeff of M.D. Anderson Cancer Center. H460-GFP cells were established as

described previously[113]. H460-GFP cells and THP-1 cells were maintained in RPMI-1640

medium. HBE4-E6/E7 cells were maintained in Keratinocyte-SFM medium (Gibco). Mouse

monocytes was isolated by negative selection with EasySspTM mouse monocyte isolation kit

according to manufacturer’s instructions (StemCell Technologies) and maintained in RPMI-1640
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medium. For some experiment, THP-1 cells were transfected with MMP-9 plasmid (HG10327-

UT, Sino Bological) by CELL PORATOR® Electroporation System (GIBCOBRL) according to

manufacturer’s instructions. After electroporation, cells were resuspended, cultured for 24 hours

and utilized for invasion or permeability assay.

2.2.2 Mice

Breeding colonies were established from CAG-LSL-EGFRvIII/+ mice and p53 floxed mice

(Trp53fl/fl) mice acquired from the NCI Mouse Repository. EP mice were generated by selective

breeding of CAG-LSL-EGFRvIII/+ mice with Trp53fl/fl mice. Adeno-cre instillation of EP mice

were performed as described in Chapter 2.1.1.

2.2.3 In vivo treatment

To induce inflammation or stress in EP mice, LPS (at 5mg/kg), Isoproterenol (at 2mg/kg),

norepinephrine (at 2 mg/kg) or in combination were used to inject intraperitoneally into EP

mice. To test non-sterol anti-inflammatory drug sulindac and β -blocker propranolol in vivo,

FWEP mice were treated with sulindac (50mg/kg/day) by oral galvage, propranolol
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(4mg/kg/day) by intraperitoneal injection, or in combination for 5 consecutive days. Mice were

sacrificed at the last treatment, tissues were harvested and fixed in 10% formalin. Whole blood

was collected and processed for InCTC assay as described[113]

2.2.4 Blood and blood component transfusion

Blood was collected from normal or FW mice by cardiac puncture. Complete blood count

was determined by Research Information Systems&Technology services at the University of

Texas MD Anderson Cancer Center. Blood was diluted with 2%FBS in PBS solution and

subjected to Ficoll-Paque(GE Healthcare) according to the manufacturer’s instruction for

gradient centrifugation to isolate peripheral blood mononuclear cell (PBMC) fraction in the

buffy layer and neutrophils in red blood cell fraction. Monocytes in PBMC fraction were

separated by negative selection (EasySep mouse monocyte isolation kit, StemCell

Technologies). For some experiments, donor FW mice were injected intravenously with GdCl3

at 20 mg/kg at 24 hours to deplete monocytes. 300uL of whole blood or blood component was

transfused to EP mice at 8 weeks post instillation via intravenous injections. To test TGF- β1

and MMP-9 effects on ETCD, TGF- β inhibitor SB431542 (Selleckchem) at 2uM or MMP-9
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inhibitor (Calbiochem, 444278) at 5uM were used to treat FW monocytes for 1 hour before

transfusion [115].

2.2.5 Invasion and permeability assay

Primary monocytes pre-treated with LPS at 50ng/mL, Isoproterenol at 1uM or in

combination for 24 hours were mixed with HBE4-E6/E7 cells at a ratio of 1:10 in serum

free RPMI-1640 medium and plated into Matrigel coated Transwell inserts for invasion

assay. For in vitro permeability assay, pretreated THP-1 cells were plated onto HUVEC

cell coated Transwell insert as described previously[116]. FW monocytes were isolated
and treated with TGF- β inhibitor SB431542 (Selleckchem) at 2uM or MMP-9 inhibitor

(Calbiochem, 444278) at 5uM for 1 hour before subjected to invasion or permeability

assay. For in vivo permeability assay, FW mice or wild type mice treat with LPS/ISO was

injected with Evans Blue solution (20mb/kg) into the retroorbital venous sinus. Mice

were sacrificed 30 min later and lungs were harvested for OD620 and OD740 recording

as described [116]
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2.2.6 Western blot analysis.

To test the effect of TGF- β1 on MMP-9expression, THP-1 or isolated monocytes were

treated with TGF- β1 at 2ng/mL for 24 hours. Treated THP-1 cells and monocytes were lysed in

RIPA lysis buffer containing complete mini protease inhibitor cocktail (Roche). Cell lysates were

analyzed for the expression of TGF- β1 and MMP-9 as previously described [117]. Antibodies to

the following proteins were used: anti-TGF-β1 (555052; BD), anti-MMP-9 (ab38898; Abcam);

and anti-β-actin (C-11; Santa Cruz).

2.2.7 Study patient selection

After approval of the institutional review board, all adult NSCLC patients undergoing lung

cancer surgery between January 2004 and December 2016 were retrospectively reviewed.

Patients with known recurrence status were selected for further analysis. Preoperative use of

aspirin and β-blocker in the patients were recorded and analyzed. The β-blockers include

atenolol, bisoprolol, labetalol, metoprolol, propranolol, and others. The patients were divided into

either using aspirin or any β-blockers or both. The recurrence rates between these groups were

calculated and compared.
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2.2.8 Statistical analysis.

All data were subjected to statistical analysis using the Excel software package

(Microsoft, Redmond, WA) or GraphPad Prism 6 (GraphPad Software, Inc, La Jolla, CA).

We compared continuous variables with either Student's t-test or analysis of variance

(ANOVA) and compared categorical variables with χ2. We used nonparametric tests (Mann-

Whitney test), if appropriate, to compare differences. We considered P < 0.05 to be

significant.
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Chapter 3 Loss of p53 is required for non-amplified EGFRvIII to induce lung
cancer in mice

3.1 Introduction

EGFRvIII mutation in human lung cancers is often associated with EGFR amplification.

However, the reason for this phenomenon is unclear. In this chapter, we established an oncogenic

EGFRvIII mutation–driven non–small cell lung cancer (NSCLC) mouse model based on the CAG-

LSL-EGFRvIII/+ allele. We found that induction of EGFRvIII mutation alone is insufficient to

induce lung tumors in mice. Concurrent loss of p53, however, enables rapid development of lung

tumors in the animal, progressing from atypical adenomatous hyperplasia to adenoma to

adenocarcinoma, associated with a mean survival time of about 15 weeks. Circulating tumor cells

were detected at the late adenocarcinoma stage of tumor development and were tumorigenic.

Blocking TGF-β signaling strongly inhibited tumor cell dissemination in this model.
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3.2 Non-amplified EGFRvIII mutation requires loss of p53 to induce lung
tumorigenesis

To study the role of non-amplified EGFRvIII mutation in lung tumorigenesis in vivo,

CAG-LSL-EGFRvIII/+ mice were inoculated with adeno-cre virus to the lung. Recombination

of EGFRvIII allele was confirmed by PCR. No tumors were observed in the mice after 18

months of inoculation (data not shown). Loss of p53 in the lung, in Trp53fl/fl mice, resulted in

lung adenocarcinoma 1 year after inoculation with adeno-cre (data not shown), consistent

with a previous report [118]. Simultaneous deletion of p53 and expression of EGFRvIII, in EP

mice, resulted in rapid development of lung tumors. Histologic analysis of the EP mouse

lungs revealed three types of lesions: atypical adenomatous hyperplasia, adenoma, and

adenocarcinoma (Figure 5a). Small, scattered atypical adenomatous hyperplasia was the

dominant lesion type at 4 weeks after infection, whereas large lung adenomas were observed

histologically at 8 weeks after infection (Figure 5b). At 12 weeks after infection, the surface

of the lungs had a cobblestone appearance, and histologic sections showed overt

adenocarcinoma (Figure 5b). The affected area in the lungs increased quickly with time, and
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55% of the total lung area was occupied by tumor cells at 12 weeks after infection (Figure

5b). The adenocarcinoma showed numerous mitoses, enlarged nuclei with prominent nucleoli,

and an undifferentiated appearance (Figure 5a). The lung tumorigenesis in EP mice resulted in

markedly shortened survival: all EP mice had died at 15-16 weeks after infection, with a

mean survival time of 105 days (Figure 5c). In contrast, the mean survival time of CAG-LSL-

EGFRvIII/+ and Trp53fl/fl mice were more than 300 days after infection (Figure 5c). These

results indicate that non-amplified EGFRvIII mutation in itself is not sufficient to induce lung

tumorigenesis, whereas concurrent loss of p53 resulted in rapid development of lung

adenocarcinoma.
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Figure 5. Analysis of tumor progression in LSL-EGFRvIII/+, LSL-Trp53fl/fl (EP) mice.
(a) Histological sections of the lungs were examined for the presence of lesions. Representative
types of lesion developed for this model. Left: Atypical adenomatous hyperplasia. Middle:
Adenoma. Right: Adenocarcinoma. Inset higher magnification (x400) of lesion. (b)
Quantification of overall number of hyperplasia, adenoma and adenocarcinomas and
quantification of overall area of lung occupied by tumor (mean values±SD.) in LSL-EGFRvIII/+,
LSL-Trp53fl/fl (EP) mice from 4 weeks to 12 weeks post adeno-cre instillation. n=6 per group.
**P<0.01 (χ2-test assessing the genotype effect in a generalized linear model with log link). (c)
The Kaplan-Meier survival curves for LSL-EGFRvIII/+, LSL-Trp53fl/fl (n=14), LSL-EGFRvIII/+
(n=12) and LSL-Trp53fl/fl mice infected by adeno-cre instillation (2.5 x 10^8 p.f.u). p<0.01(longrank test) between the LSL-EGFRvIII/+, LSL-Trp53fl/fl cohort and controls.
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3.3 Late tumor cell dissemination in EP mice

Although EP mice developed aggressive lung adenocarcinoma, we did not observe

macrometastasis in any organs at 12-16 weeks after infection. To determine the presence of

CTCs in the EP mice, we used an assay that we recently developed to detect and enumerate

CTCs on the basis of their invasiveness [113]. We did not detect any CTCs in EP mice before

13 weeks after infection (data not shown). After 13 weeks, when tumors had developed into

adenocarcinomas numerous invasive epithelial cells with positive cytokeratin and negative

CD45 staining were detected (Figure 6a and figure 6b). To confirm that these cells were from

lung tumors, we used a PCR-based method to detect the recombination junction of p53 and

showed that both CTCs and tumor cells in the lung displayed a 612-bp PCR product of the

recombinant p53 allele, demonstrating that the CTCs originated from tumor cells located in

the lung (Figure 6c).
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Figure 6. Isolation and Identification of invasive CTCs in EP mice.
(a) Comparison of CTC numbers can be detected by InCTC from 8 weeks to 14 weeks. n=6 per
group. Values are mean values±SD. *P<0.05. (b) Immunofluorescence staining of CTCs. Nuclei
were visualized by DAPI staining (blue). Cytokeratin-positive cells (red) were visualized under a
fluorescent microscope. Representative pictures are shown. (c) PCR analysis of p53
recombination in CTCs (Right). The 283 bp band represents the floxed p53 allele (Primer 1F and
1R), and the 612 bp band represents the recombined p53 allele (primers 1F and 10R). InCTC:
DNA extracted from InCTC transwell membrane containing invaded CTCs and leukocytes DNA
extracted. Tumor: DNA extracted from LSL-EGFRvIII/+, LSL-Trp53fl/fl lung tumor. InCTC control:
DNA extracted from control InCTC transwell membrane containing only leukocytes. Control:
DNA extracted from normal lung of LSL-EGFRvIII/+, LSL-Trp53fl/fl mice.
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3.4 CTCs have tumor-forming capacity in syngeneic wildtype mice.

To demonstrate the tumor-forming capacity of the CTCs of the EP mice, we

amplified the CTCs by culturing them in vitro. The mixture pools of CTCs were injected

subcutaneously into C57BL/6J wild-type mice. Rapidly growing tumors developed in all the

mice injected (Figure 7a). Within 10 days of implantation, we observed palpable tumors, and

the mean doubling time of the tumor volume was 15 days (Figure 7a). Histologic analysis

revealed that the tumors had numerous mitoses, enlarged nuclei with prominent nucleoli, and

an undifferentiated appearance (Figure 7b). These results suggest that tumor cell

dissemination occurs at a late stage of tumor development in EP mice. The short lifespan of

these mice limited the detection of macrometastasis in this model.
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Figure 7. CTCs have tumor-forming capacity in syngeneic wildtype mice.
(a) Subcutaneous tumor growth curve of invasive CTCs in C57BL/6J mice. n=6 for this
experiment. (b) Histological sections of tumor in C57BL/6J mice subcutaneously inoculated with
invasive CTCs.
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3.5 Blocking TGF- β signaling inhibited tumor cell dissemination in EP mice

Emerging evidence has showed that the TGF-β signaling pathway plays an important

role in promoting tumor metastasis [119]. Therefore, we determined whether blocking TGF-β

signaling could inhibit tumor cell dissemination in EP mice. SB431542 is a small-molecule

tyrosine kinase inhibitor of TGF-β [120]. Short-term treatment (1 week) of 13-week-old EP mice

with SB431542 did not cause any detectable morphology change or growth of primary tumors

(data not shown). SB431542 treatment did strongly inhibit tumor cell dissemination in EP mice,

as very few CTCs were detected in the treatment group, while a mean of 50 CTCs/mL were seen

in the control group (Figure 8). This result suggests that TGF-β inhibition dramatically decreases

tumor cell dissemination in EP mice.
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Figure 8. Effect of SB431542 on tumor dissemination of EP mice.
Comparison of CTCs numbers of LSL-EGFRvIII/+, LSL-Trp53fl/fl mice at week 14 post adeno-cre
instillation with or without SB431542 treatment. n=6 per group. Values are mean values±SD.
*P<0.05.
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3.6 Conclusion and Discussion

In this chapter, my results indicate that non-amplified EGFRvIII mutation requires

concurrent loss of p53 to induce lung cancer and that inhibition of TGF-β is potentially an

effective therapeutic approach to prevent metastasis in NSCLC. On the basis of this study and

previous studies, we conclude that EGFRvIII mutation requires either an increased level of

expression through gene amplification and other mechanisms or concurrent loss of tumor

suppressors to initiate NSCLC tumorigenesis. These mechanisms could be utilized for clinical

diagnosis and treatment.

Previous reports show that EGFRvIII mutation is highly correlated with EGFR

amplification in both human glioma and lung cancer [33, 121], suggesting that overexpression

of EGFRvIII mutation is required for tumor formation. This notion is further supported by the

findings that expression of non-amplified EGFRvIII mutant does not induce malignant

transformation in the mouse brain and that overexpression of EGFRvIII mutant in the mouse

lung under the control of a tetracycline-inducible promoter resulted in the development of

lung adenocarcinoma [30, 32]. Our present findings further support that non-amplified
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EGFRvIII mutation alone, without other mechanisms such as concurrent loss of tumor

suppressors, is not sufficient to induce lung cancer.

Compelling evidence indicates that the roles of TGF-β in tumor suppression and

progression depend on context and stage [119]. TGF-β promotes cancer metastasis through

various programs that influence the tumor microenvironment, enhance invasive properties,

and inhibit immune cell function [122]. Indeed, increased TGF-β1 expression in NSCLC is

correlated with poor prognosis, while intense TGF-β staining in several cancer types has been

correlated with metastasis [123]. In the present study, we showed that inhibition of TGF-β

signaling strongly diminishes the appearance of CTCs in the blood, providing the first direct

evidence of the involvement of the TGF-β signaling pathway in the tumor cell dissemination

process. This result suggests that small-molecule inhibitors of TGF-β receptor kinase activity

may be used as new therapeutics to prevent metastasis in NSCLC.

In summary, EGFRvIII mutation must be either amplified or accompanied by tumor

suppressor loss for lung cancer development, and the EP mouse is a useful model for

investigating EGFRvIII-driven NSCLC progression and for developing new therapies for lung
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cancer. Moreover, TGF-β inhibition is a potential strategy for preventing NSCLC metastasis and

should be investigated in large cohort clinical trials.
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Chapter 4. Characterization of the molecular mechanism of early tumor
dissemination in non-small cell lung cancer

4.1 Introduction

Emerging clinical evidence suggests early tumor cell dissemination (ETCD) occurs in

NSCLC [42, 124]. However, tumor cell dissemination was only detected at an advanced

adenocarcinoma stage in Kras-driven NSCLC mice [45]. Similarly, as detailed in the previous

chapter, we could only detect CTCs at a late stage of adenocarcinoma (14 weeks) in EP mice

we recently established [44]. These results suggest that additional events are required for

ETCD to occur in these models.

Serendipitously, we detected CTCs stained positive for epithelial cell marker cytokeratin

and negative for lymphocyte marker CD45 in young EP mice with cutaneous wounds caused

by fighting (fight-wounded EP, or FWEP mice) as early as 4 weeks after the initiation of

tumorigenesis (Figure 9a and figure 9b). The tumor analysis confirmed that adenomatous

hyperplasia is the main lesion found at 4 weeks and adenoma at 8 weeks in these mice (Figure

9c). The presence of the floxed p53 allele in the CTCs supports that they are from primary
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lung tumors (Figure 9d). The fighting wound-induced early tumor cell dissemination was also

observed in the Kras-driven NSCLC mice (Figure 10). The tumor analysis also confirmed that

adenoma is the main lesion found at 12 weeks post instillation in KrasG12D mice. CTCs were

not detected in fight-wounded wild type or non-infected EP mice (Figure 10), suggesting that

fighting wounds do not induce the release of normal lung epithelial cells into the blood

stream.
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Figure 9. Detection of CTCs in EP mice.
(a) Representative immunofluorescence staining of CTCs in FWEP mice as detected by the
InCTC assay. Nuclei were visualized by DAPI staining (blue). PanCytokeratin-positive cells (red)
and CD45-positive cells (green) were visualized under a fluorescent microscope. (b) Quantitation
of CTCs in control EP and FWEP mice both at 4 weeks and 8 weeks post viral instillation. Data
are derived from 5 mice per group. (c) H&E staining images of representative lung tumor
morphology at week 4 and week 8 post instillation. (d) PCR verification on the identity of the
CTCs. The 283 bp band represents the floxed p53 allele and the 612 bp band is the non-floxed
p53 allele. M stands for DNA marker. **P<0.01.
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Figure 10. Detection of CTCs in LSL-KrasG12D mice.
Quantitation of CTCs in FWWT mice and FWKras mice at 12 weeks post viral instillation. Data
are derived from 5 mice per group. **P<0.01.
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4.2 Early disseminated tumor cells are tumorigenic.

One key question regarding ETCD is whether these CTCs are in a dormant or

tumorigenic state. So, we harvested PBMCs from FWEP mice at 8 weeks post instillation and

a small number of CTCs (<100) contained in the PBMC were transfused back to wild type

syngeneic mice. 5 out of 6 mice developed tumors in the lung, liver and abdominal cavity

within 52 weeks (Table 2 and figure 11). These results indicate that fighting wounds are one

of the factors required to induce ETCD in lung cancer mice and that the early disseminated

tumor cells are highly tumorigenic.
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Table 2. Tumor formation and dissemination site of control PBMC or CTC transfused
syngeneic mice.
A small number of CTCs (<100) or control PBMC harvested from young FWEP mice were
transfused back to wild type syngeneic mice. 5 out of 6 mice developed tumors in the lung, liver
and abdominal cavity within 52 weeks.
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Figure 11. Gross morphology and H&E staining of lung and liver tumors formed by CTCs
of FWEP mice.
PBMC harvested from one FWEP mouse at 8 weeks post instillation were transfused into a wild
type syngeneic mouse via tail vein. The recipient mice were monitored for health and sacrificed at
10 to 52 weeks post transfusion. Presence of tumors (indicated by arrows) in the lung, liver and
other organs were analyzed and representative images are shown. The bar represents 50 μm.
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4.3 Combination of inflammation and stress is sufficient to induce ETCD.

Fighting is a common phenomenon in male laboratory mice and results in various

neurological, behavioral and immunological changes [125, 126]. The FWEP mice suffered

from psychological stress with agnostic behavior and inflammation as a result of cutaneous

wounds. This observation prompted us to test the effects of stress inducers and stimulants of

inflammation in inducing ETCD in non-fighting EP mice (Figure 12). We applied

Lipopolysaccharide (LPS) to induce systemic inflammation [127] and stress from either

physical restraint or chemical stressors like isoproterenol (ISO) or norepinephrine (NE) [90,

128]. Notably, application of either LPS or stress inducers alone is not sufficient to induce

ETCD in EP mice as measured by the presence of CTCs. Only the combination of

inflammation and stress enabled tumor cells to disseminate into blood stream (Figure 12).

Similar findings were obtained in Kras-driven lung cancer mice (Figure 13)
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Figure 12. Involvement of acute stress and inflammation in ETCD of EP mice.
Effects of LPS, physical restrain stress, ISO, NE or in combination on ETCD. EP mice at 8 weeks
post instillation were treated as indicated and CTCs in these mice were quantified. Data are
derived from 5 mice per group. **P<0.01
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Figure 13. Involvement of acute stress and inflammation in ETCD of LSL-KrasG12D mice.
Effects of LPS, ISO, or in combination on ETCD. LSL-KrasG12D mice at 12 weeks post
instillation were treated as indicated and CTCs in these mice were quantified. Data are derived
from 5 mice per group. **P<0.01
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4.4 Role of monocytes in ETCD

Both psychological stress and inflammation were reported to modulate immune responses

and immune cells redistribution [89, 129]. Therefore, we proceeded to investigate the

involvement of peripheral blood and blood components like immune cells in ETCD (Figure 14a).

Transfusion of either whole blood, peripheral blood mononuclear cells (PBMC), or monocytes

from fight-wounded wild type syngeneic mice to young non-wounded EP mice (bearing

adenomas and hyperplasia) induced various degrees of ETCD in the recipient mice, while the

transfusion of plasma or of red blood cells (RBC) and neutrophils had no effect (Figure 14a).

Transfusion of blood from non-wounded mice also showed no effect (Figure 14a). More

importantly, depletion of monocytes in the donor blood completely blocked ETCD in the

recipient EP mice (Figure 14a). We measured blood cell counts in control, fight-wounded, and

ISO/LPS treated mice and identified a significant increase of monocytes in the fight-wounded,

and ISO/LPS treated group when compared to the controls (Figure 14b). This result is consistent

with the notion that monocytes are involved in stress and inflammation-mediated ETCD. Other

blood cells including RBC, lymphocytes, neutrophils and platelets did not show significant
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changes (Figure 14b). Similar findings were obtained in Kras-driven lung cancer mice (Figure

15). These data support the hypothesis that the combination of inflammation and stress act on

monocytes to induce ETCD in lung cancer mice.
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Figure 14. Role of monocytes in ETCD of EP mice.
(a) Involvement of blood and blood components in ETCD. EP mice at 8 weeks post instillation
were transfused with whole blood or blood components harvested from FW mice as indicated and
CTCs in these mice were quantified. Data are derived from 5 mice per group. (b) Effect of acute
stress and inflammation on blood counts. Data are derived from 6 mice per group. **P<0.01.
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Figure 15. Role of monocytes in ETCD of LSL-KrasG12D mice.
Involvement of blood and blood components in ETCD of LSL-KrasG12D mice. LSL- KrasG12D
mice at 12 weeks post instillation were transfused with whole blood or blood components
harvested from FW mice as indicated and CTCs in these mice were quantified. Data are derived
from 5 mice per group. **P<0.01.
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4.5 Activated monocytes induce the invasiveness of adenoma cells and leakiness of
blood vessels.

The next question we investigated is how activated monocytes promote ETCD in lung

cancer mice. During analysis of lung tumors in FWEP mice, we noticed the presence of blood

cells outside of blood vessels in the lung (Figure 16a), suggesting that these blood vessels are

leaky. To confirm this observation, we measured vascular permeability in vivo and showed a

significant increase of blood vessel leakiness in the lung of FWEP mice compared to control EP

mice (Figure 16b). We next measured the effect of monocytes on endothelial permeability in vitro

(Figure 17a). We observed that pretreatment of normal primary monocytes with the combination

of LPS and ISO significantly increased the permeability of human umbilical vein endothelial cells

(HUVEC) monolayer compared to controls while single treatment had no significant effect

(Figure 17a). We further showed that pretreatment of normal primary monocytes with the

combination of LPS and ISO promoted the invasion of both immortalized lung epithelial cells

(pre-cancer) and lung cancer cells in vitro (Figure 17a and figure 17b). These results were also

observed in THP-1 monocytotic cells (Figure 18a and figure 18b). The pretreatment of THP-1
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cells increased the permeability of the HUVEC monolayer and promoted the invasion of both

immortalized lung epithelial cells and lung cancer cells. In summary, these results confirm that

stress and inflammation signals activate monocytes to promote ETCD by enhancing both vascular

permeability and tumor cell invasiveness.
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Figure 16. Lung blood vascular leakage induced by fighting-wound.
(a) H&E staining images of representative of vascular leakage of FWEP mice at week 8 post
instillation. (b) Lung permeability of FWEP and ISO/LPS combination treated mice were
measured by FITC-dextran normalized to control. ***P<0.005.
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Figure 17. Effect of LPS- and ISO-activated monocytes on endothelial permeability and
tumor cell invasion
(a) Primary monocytes pretreated by LPS, ISO or in combination were co-cultured with HBE4
cells in transwells for invasion assay and with HUVEC monolayer for permeability assay. (b)
Primary monocytes pretreated by LPS, ISO or in combination were co-cultured with H460 cells
in transwells for invasion assay *P < 0.05
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Figure 18. Effect of LPS- and ISO-activated THP-1 cells on endothelial permeability and
tumor cell invasion
(a) THP-1 cells pretreated by LPS, ISO or in combination were co-cultured with HBE4 cells in
transwells for invasion assay and with HUVEC monolayer for permeability assay. (b) THP-1 cells
pretreated by LPS, ISO or in combination were co-cultured with H460 cells in transwells for
invasion assay *P< 0.05.
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4.6 Induced expression of TGF- β1 and MMP-9 in monocytes as the mechanism of
ETCD.

To further dissect the mechanism of monocyte-mediated activity in blood vessels and tumor

cells, we examined the expression of matrix metalloproteinases (MMP) by MMP antibody array

since MMPs are known to participate in local invasion and intravasation of tumor cells [90, 110]

(Figure 19). We identified that levels of MMP-9 were significantly increased in monocytes

isolated from FW mice, in normal primary monocytes treated with LPS/ISO, and in (the human

monocytic cell line) THP-1 cells treated with LPS/ISO compared to controls (Figure 20). TGF-β1

has the broadest spectrum of effects in the cutaneous wound healing process and was reported to

induce MMP-9 expression in various epithelial cells [21, 110, 130]. We measured the expression

of TGF-β1 and found enhanced levels of mature TGF-β1 in both monocytes isolated from FW

mice, in normal primary monocytes treated with LPS/ISO, and in THP-1 cells treated LPS/ISO

compared to controls (Figure 20). We further confirmed that TGF-β1 is able to stimulate MMP-9

protein expression in mouse monocytes and THP-1 cells (Figure 21). To determine the

functionality of TGF-β1 and MMP-9 in early tumor cell dissemination, we first treated FW
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monocytes with either TGF-β inhibitor (SB431542) or MMP-9 inhibitor (444278) [120, 131].

The activities of the inhibitors were confirmed by analysis of smad2 and smad3 phosphorylation

status or by measurement of endothelial permeability and tumor cell invasion (Figure 22b and

figure 23b). We next transfused inhibitor-treated monocytes into EP mice and detected a dramatic

decrease in the ability of inhibitor-treated FW monocytes to induce the release of CTCs in the

blood streams of recipient EP tumor mice (Figure 22a and figure 23a). Overexpression of MMP-9

in monocytic THP-1 cells promoted HUVEC monolayer permeability and tumor cell invasion in

vitro (Figure 24). These results suggest that the combination of inflammation and stress induces

the expression of TGF-β1 and MMP-9 in monocytes to enhance both vascular permeability and

tumor cell invasiveness, thus leading to early tumor cell dissemination.
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Figure 19. MMP antibody array identified MMP-9 as a downstream mediator
(a)THP-1 cell treated with LPS, ISO and in combination was assayed using a human MMP
antibody array. (b) Quantitation of array signals by image analysis. Intensity of signals was
normalized to saline-treated control samples, and results are expressed as fold increases.
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Figure 20. Increased expression of TGF-β1 and MMP-9 in the monocytes of FWEP mice
and in THP-1 cells treated by LPS, ISO, and in combination.
(a) Western blot analysis of TGF-β1 and MMP-9 expression in monocytes isolated from EP and
FWEP mice. Normal Mo indicates monocytes isolated from EP mice. FWMo indicates
monocytes isolated from FWEP mice. (b) Western blot analysis of TGF-β1 and MMP-9
expression in primary monocytes treated with LPS, ISO, and in combination. (c) Western blot
analysis of TGF-β1 and MMP-9 in THP-1 cells treated with LPS, ISO and in combination.
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Figure 21. Induction of MMP-9 by TGF- β1 in mouse monocytes and THP-1 cells.
(a) Western blot analysis of MMP-9 expression induced by TGF-β1 in mouse monocytes. (b)
Gelatin Zymography analysis of MMP-9 activity induced by TGF-β1 in THP-1 cells. *P < 0.05.
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Figure 22. TGF-β inhibitor inhibited ETCD.
(a). Quantification of CTCs detected in EP mice bearing adenomas transfused with FWMo and
TGF-β inhibitor (SB431542)-treated monocytes. Data are derived from 6 mice per group. (b)
Time course of Smad2, Smad3, phospho-smad2 and phospho-smad3 expression in primary
monocytes treated with TGF-β and TGF-β inhibitor. ***P < 0.005.
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Figure 23. MMP-9 inhibitor suppressed ETCD.
(a). Quantification of CTCs detected in EP mice bearing adenomas transfused with FWMo and
MMP-9 inhibitor-treated monocytes. Data are derived from 6 mice per group. **P <0.01. (b) In
vitro permeability and invasion assay in FWEP monocytes and FWEP monocytes treated with
MMP-9 inhibitor or TGF-β inhibitor. Relative intensity was measured by FITC-dextran
normalized to control. Results were derived from three independent experiments. **P<0.01,
***P<0.005.

70

Figure 24. Effect of MMP-9 overexpression in THP-1 cells on endothelial permeability and
tumor cell invasion
(a) Western blot analysis of MMP-9 overexpression in THP-1 cells transfected with MMP-9
plasmid. (b) Effect of MMP-9 overexpression in THP-1 cells on endothelial permeability and precancer cell invasion. MMP-9 overexpression in THP-1 cells were co-cultured with HBE4 cells in
transwells for invasion assay and with the HUVEC monolayer for permeability assay. **P<0.01.
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4.7 Simultaneous targeting of inflammation and stress inhibits ETCD.

As we have demonstrated that the combination of inflammation and stress induces ETCD in

lung cancer models, we decided to determine the effect of an anti-inflammatory drug and a β-

adrenergic blocking agent on ETCD. Sulindac, a commonly used anti-inflammatory drug, and

propranolol, a potent β-blocker were chosen in our studies [90, 132, 133]. When FWEP tumor

mice were treated with either sulindac, propranolol or both, only the combination treatment

decreased the expression of mature TGF- β1 and MMP9 in monocytes (Figure 24b). Also,

treatment of either sulindac or propranolol alone had no effect on the number of CTCs while the

combination of both drugs significantly reduced the number of CTCs in the FWEP mice (Figure

24a). These results indicate that simultaneous targeting of inflammation and stress with an anti-

inflammatory drug and a β-adrenergic blocking agent can inhibit ETCD.
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Figure 25. Effect of sulindac and propranolol treatment on ETCD.
(a) Effect of sulindac and propranolol treatment on ETCD. FWEP mice were treated with either
sulindac, propranolol or the combination. CTCs in the treated mice were quantified and plotted.
Data are derived from 6 mice per group. (b) Effect of sulindac and propranolol treatment on the
expression of TGF- β1 and MMP-9 in monocytes. FWEP mice were treated with either sulindac,
propranolol or the combination. Expression of TGF-β1 and MMP-9 in monocytes were analyzed
by Western blots. ***P<0.005.
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4.8 Retrospective analysis of clinical data

To investigate the relevance of our animal studies to human studies, we analyzed data

collected from NSCLC patients treated at The University of Texas MD Anderson Cancer

Center during the period of 2004 to 2016 with known recurrence status. A total of 2,085

patients with Stage I to III NSCLC were included in this analysis (Table 3). Because the

history of inflammation and stress were unknown in this retrospective database, we decided to

investigate the effect of aspirin uptake (a commonly used medication to treat pain, fever,

inflammation and blood thinning) [134-136] and the usage of β-blockers (commonly used for

managing hypertension) on the rate of recurrence in this data set [137, 138]. The results

showed that use of either aspirin or β-blockers had a no significant effect on the recurrence

while patients using both drugs had a markedly reduced rate of recurrence compared to non-

users (21.1% vs 32.4%, p < 0.05, Table 3). The difference in rate of recurrence between

aspirin plus β-blocker users and total population was also significant (21.1% vs 30%, p <

0.05, Table 3). These data strongly support our animal studies in that the combination of

inflammation and stress is a major risk factor for NSCLC recurrence and that blocking these
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processes using anti-inflammatory drugs and β-blockers can decrease the rate of recurrence

significantly.
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Table 3. Effect of aspirin and β-blocker use on lung cancer recurrence
NSCLC patients with known recurrence status treated at MDACC from 2004-2016 were
analyzed. Pairwise comparison was performed for each group vs Total. P-value was calculated
using chi-squared test. Asp+: aspirin user. Asp-: aspirin non-user. BB+: β-blocker user. BB-: βblocker non-user. * represents P < 0.05.
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4.9 Conclusion and Discussion

Both chronic inflammation and excessive stress are known to promote tumorigenesis and

reduce survival in cancer [67, 69, 139]. Stress and inflammation are also interrelated as various

studies demonstrate that stress increases inflammation at the cellular level [140]. However, what

we discovered in this study is that acute stress and inflammation, which are considered beneficial

to human health, can induce deleterious effects when occurring at the same time. Because acute

stress and inflammation are common events in daily life, it could contribute to the high relapse

rate found in human lung cancer. Fortunately, we demonstrate that the treatment of an anti-

inflammatory agent along with a β-blocker blocks ETCD in mice. Also, NSCLC patients using

both aspirin and β-blockers showed a significant decrease risk of recurrence, proposing a

potential remedy. However, this discovery needs to be validated and further investigation of the

effect of drug dosage, duration of drug exposure, and difference between various β-blockers is

needed.

In conclusion, we discovered that the combination of acute inflammation and stress is able to

activate monocytes to promote ETCD in NSCLC mouse models. We identified that the enhanced
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expression of TGF-β1 and MMP-9 in monocytes operate as downstream mediators to augment

vascular permeability and invasiveness of tumor cells. We further demonstrated the preventive

potential of anti-inflammatory drugs and β-blockers in reducing ETCD. Our study provides a

retroactive analysis that uses the history of aspirin and β-blocker usage as an indicator to assess

recurrence risk in NSCLC patients as well as experimental groundwork in using these drugs to

prevent ETCD and recurrence in people with high risk of developing lung cancer.
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Chapter 5 Summaries and Discussion

5.1 Early cancer detection

Cancer is among the most life threatening diseases in the U.S. and worldwide. Metastasis

is the cause of 90% cancer patient deaths. Once local or distant metastasis has occurred, the

efficacy of resection surgery or radiological therapy is limited [53]. One major goal in the

cancer research field is to detect tumors at a pre-malignant stage or early stage before

metastasis happens. For cervical, breast and colorectal cancers, screenings are currently

recommended. Screening methods consist of cervical cytology, mammography and

colonoscopy and are definitely beneficial to the at-risk populations in terms of decreasing

cancer morbidity at various levels [3]. However, limitations, such as increased anxiety from

false-positive results, increased medical expenses and discomfort or invasiveness to the

patients, seriously compromise the benefits. The same limitations also apply to lung cancer

screening with LDCT. The measurement of prostate specific antigen (PSA) in blood is

commonly used for prostate cancer early detection, but the proper use of this test is still under

debate [141]. Therefore, a highly accurate and noninvasive early cancer detection approach is

79

sorely needed. Recent major advances in the understanding of early tumor dissemination in

various cancer types and the capability of detecting and characterizing CTCs and circulating

tumor DNA (ctDNA) have introduced the possibility of applying CTCs and ctDNA for early

cancer detection [35, 56, 57]. The methods to enumerate and identify CTCs have been

described in Chapter 1. These methods have been applied in distinct studies to identify CTCs

in populations of high risk and exhibited promising results. Ilie et., al applied the ISET

filtration-enrichment technique for CTC isolation and identified CTCs in 3% of chronic

obstructive pulmonary disease (COPD) patients. Later, surgical resection and

histopathological analysis confirmed the existence of early-stage lung cancer [142]. In a large

cohort of 542 patients (including cancer patients and high risk populations), researchers have

detected CTCs in a small proportion with normal PSA levels in plasma, but the subsequent

positive PSMA-PET scans revealed early prostate cancer [143]. Moreover, using CTCs as a

biomarker enables us to visualize cell morphology, characterize both cellular and sub-cellular

molecular evidence and allow functional assays in vitro/in vivo like xenotransplantation of

CTCs into immunocompromised mice [57, 144]. In our lab, we have established the InCTC
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assay to identify invasive CTCs and we have also applied our method in the pre-malignant

ApcMin/+ mouse model of colon cancer and FAP patients (Figure 25 and figure 26). The results

indicate that CTCs are detected as early as 5 weeks in ApcMin/+ mice when an average of only

2 polyps can be detected. Furthermore, we also identified CTCs in FAP and non-FAP

polyposis patients, but not healthy donors. Using a method described by Gerecke et. al. [145],

we detected multiple APC gene mutations in CTC samples from FAP patients and confirmed

the origin of the CTCs is polyps.
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Figure 26. Detection of CTCs in pre-malignant ApcMin/+ mice.
Identification and analysis of CTCs by InCTC and FISH. Blood samples from either ApcMin/+
mice or wild type mice were subjected to InCTC. Nuclei were visualized by DAPI staining (Blue)
and cytokeratin-20 positive cell (Green) under a fluorescent microscope. Fluorescence in situ
hybridization (FISH) was performed on the invaded cells collected after InCTC from 12 weeks
old ApcMin/+ mice. Chromosome 18 probe (Red) and nucleus staining with DAPI (Blue) are
shown. The experiments were repeated multiple times and representative images are shown.
Adapted from Wu’s lab, contribution by Vineet Gupta Ph.D., Xingtong Liu
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Figure 27. Detection of CTCs in FAP and HNPCC patients with InCTC assay.
Presence of CTCs in human polyposis patients. (a) InCTC assay was performed on blood samples
from the healthy donors and polyposis patients. Representative images from FAP patients were
shown. (b) Mutational analysis of CTCs. DNA was extracted from CTCs of healthy donors and
FAP patients. APC mutations were analyzed by an APC mutation detection method as described.
LNA blockers were used to suppress the wild type but not of mutated APC products.
Adapted from Wu Lab, contribution by Vineet Gupta Ph.D.
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CtDNA is comprised of small fragments of nucleic acids that are shed from tumors and

are not associated with cell fragments or cells. Recent advances in sequencing techniques

allow us to collect abundant genetic information with a limited ctDNA concentration in

plasma. The use of targeted sequencing, exomic sequencing and whole-genome sequencing in

studies from Bettegowda et al. have shown that ctDNA was detected in patients with localized

tumors, including colorectal cancer, gastroesophageal cancer, pancreatic cancer, and breast

adenocarcinoma varying from 47% to 75% [146]. The limitation of this study lies in the fact

that it requires a pre-designed panel of gene mutations to define ctDNA in plasma. This

problem was addressed by another study that utilized targeted error correction sequencing

(TEC-Seq); it allows sensitive and specific detection of low-abundance sequence alterations.

Based on this study, somatic mutations were detected in the plasma in the early stage of

various solid tumors ranging from 59% to 71% [147]. Previous studies reported that a

proportion of early stage tumors do not release a detectable amount of ctDNA. To overcome

this issue, a multi-analyte blood test named cancerSEEK was developed and it utilizes ctDNA

in combination with 39 protein biomarkers for early cancer detection. CancerSEEK is
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reported to detect ctDNA in a median of 70% of the eight chosen cancer types [148]. All in

all, there is urgent need to develop highly accurate and noninvasive methods for cancer early

detection. Advances in detection techniques make CTCs and ctDNA promising biomarkers

for the early detection of cancer.

5.2 Management of NSCLC recurrence

The recurrence rate after complete resection surgery remains high for patients at the early

stage of NSCLC and little advance has been made in the past 30 years. The reason might be

attributed to ETCD in NSCLC. In this thesis, I have identified the combination of inflammation

and acute stress as an independent risk factor for NSCLC recurrence. Both acute stress and

inflammation are common in daily life. 77% of people in the U.S. regularly experienced physical

symptoms caused by stress from working pressure, economic issues, and health concerns such as

chronic or terminal diseases [149]. Our results indicate the deleterious effect by the combination

of acute stress and inflammation. These results suggest that we should monitor and manage the

psychological stress and inflammation status in NSCLC patients.

We have uncovered a molecular pathway initiated by the inflammation and stress signals to
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activate monocytes as the major cell type to induce ETCD in the mouse model of NSCLC.

Regardless of the fact that this finding is exciting and promising, several main questions still need

to be addressed in the future. First, both inflammation and stress are complex processes that

include an excessive involvement of signaling pathways and numerous cell types. Thus, to fully

understand the combinational signaling effect of these two processes requires additional study.

Secondly, it would be an extreme priority to understand the applicability of the combinational

signal in inducing ETCD. It is essential to determine whether this observation is gene-specific or

tissue-specific. Up until now, we tested the combination of inflammation and stress in mouse

models of LSL-KrasG12D-driven NSCLC, Kras-driven pancreatic and ApcMin/+ for FAP. We

verified that the combination of inflammation and stress induced ETCD in LSL-KrasG12D-driven

NSCLC mice but not in Kras-driven pancreatic mice or ApcMin/+ mice. This indicates that the

combination-induced ETCD may be a tissue-specific effect. Since we only had access to limited

genetic mouse models with specific gene or cancer types, it still requires additional studies to

generate a convincing conclusion. Third of all, we showed that activated monocytes are critical to

ETCD. However, monocytes may not represent a reasonable target of intervention because
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monocytes are required for tissue homeostasis and immunity. Sub-populations of monocytes are

reported to play a contradictory role in regulating tumor dissemination [94, 95, 150]. Therefore,

isolation and characterization of the exact subpopulation of monocytes also needs further

investigation. Finally, we have observed a complete preventive role of combining NSAIDs and β-

blockers in EP mice; no damage has been seen in the mice in the short-term treatment. The

combination of these two drugs may require a large cohort to determine the effect of drug dosage,

the duration of drug exposure, and the difference between various β-blockers as well as side

effects introduced by the combination.
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